Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06651281 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
A Phase 3 study of Crohn Disease and Colitis, Ulcerative, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,380
- Enrollment target
- 20
- Study locations
NCT06651281 is a Phase 3 study of Crohn Disease and Colitis, Ulcerative that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,380 participants, above the 186-participant average among 71 other Crohn Disease trials with a reported enrollment target (642% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06651281, a Phase 3 study of Crohn Disease and Colitis, Ulcerative, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,380 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, and if people tolerate it.
Conditions Studied
Interventions
- DRUG Tulisokibart
- DRUG Placebo to tulisokibart
Study Locations (20)
Texas
- GI Alliance - Digestive Health Associates of Texas - DHAT ( Site 0290) - Garland
- GI Alliance - Lubbock ( Site 0288) - Lubbock
- Caprock Gastro Research ( Site 0293) - Lubbock
- Southern Star Research Institute ( Site 0299) - San Antonio
- GI Alliance - Southlake ( Site 0298) - Southlake
- Tyler Research Institute ( Site 0294) - Tyler
Other
- Hepato-Gastroenterologie HK ( Site 0700) - Hradec Králové
- ARENSIA Exploratory Medicine Georgia ( Site 1104) - Tbilisi
Connecticut
- Connecticut Clinical Research Institute ( Site 0297) - Bristol
Michigan
- St. Joseph Mercy Hospital - Huron Gastroenterology Associates ( Site 0287) - Ypsilanti
Missouri
- BVL Research - Kansas ( Site 0292) - Liberty
New York
- New York Gastroenterology Associates ( Site 0253) - New York
Virginia
- University of Virginia Health System ( Site 0291) - Charlottesville
Washington
- Washington Gastroenterology - Tacoma ( Site 0295) - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,380 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2037-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06651281
The ClinicalTrials.gov registry entry for NCT06651281 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,380 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 71 other Crohn Disease trials with a reported enrollment target (642% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Tulisokibart is the first listed.
NCT06651281 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Other, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06651281 about?
NCT06651281 is a clinical study titled "Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)". Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in c...
What is the current status of trial NCT06651281?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,380 participants. The study started on 2024-11-25. Estimated completion is 2037-12-17.
What conditions does trial NCT06651281 study?
This clinical trial studies the following conditions: Crohn Disease, Colitis, Ulcerative.
What interventions are being tested in trial NCT06651281?
The interventions under investigation include: Tulisokibart (DRUG), Placebo to tulisokibart (DRUG).
Who is sponsoring clinical trial NCT06651281?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06651281 being conducted?
This trial has 20 study locations across Connecticut, Michigan, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
COMPLETED · Phase 3
-
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
COMPLETED · Phase 3
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.